This feature highlights changes in clinical trial organizations’ personnel.

Aerin Medical

Matt Brokaw has taken the helm of private medtech company Aerin Medical as its new CEO. Prior to this appointment, Brokaw was vice president of sales and marketing at Smith and Nephew.

Amylyx Pharmaceuticals

Tammy Sarnelli has been named global head of regulatory affairs at Amylyx Pharmaceuticals. Prior to this new role, Sarnelli was executive director of regulatory affairs at Bioverativ.

Apic Bio

Gene therapy company Apic Bio has appointed Jorge Quiroz to executive vice president and chief medical officer. Quiroz was the head of neurodevelopment and psychiatry, translational medicine neurosciences at F. Hoffmann-La Roche prior to joining Apic.

Atea Pharmaceuticals

Atea Pharmaceuticals recently named Arantxa Horga as executive vice president of clinical sciences. Most recently, Horga was vice president of pharmacovigilance and medical affairs at Biohaven Pharmaceuticals. Mihaela MacNair, former senior director of global regulatory affairs and regulatory therapeutic area head at Biogen, was also hired by Atea to assume the role of vice president of regulatory affairs.

Axol Bioscience

Liam Taylor, former chief financial officer and managing director of BBI Solutions, has been named CEO of Axol Bioscience.

Bionano Genomics

Bionano Genomics has appointed Alka Chaubey to the position of chief medical officer. Chaubey was previously head of cytogenomics at Perkin Elmer Genomics.

BlueSphere Bio

BlueSphere Bio has named James Onuffer vice president of product development in preparation for a clinical program. Onuffer joins BlueSphere Bio from F1 Oncology, where he served as vice president of synthetic biology and immunology.

Cyxone

Cyxone has appointed Christin Bokedal to head of development. Bokedal joins Cyxone from Teva Sweden, where she served as the medical operations officer.

Evoke Pharma

Christopher Quesenberry has been named chief commercial officer for Evoke Pharma’s nasal spray product. Quesenberry most recently served as vice president of global commercial effectiveness at Nalpropion Pharmaceuticals.

Harpoon Therapeutics

Harpoon Therapeutics has hired Karin Thacker to the role of vice president of regulatory affairs and quality assurance.

Immunovant

Immunovant has appointed Michael Elliott to the role of chief scientific officer. Formerly, Elliott was vice president of immunology scientific innovation at Johnson & Johnson.

Immunovia

Immunovia has named Patrik Dahlen the company’s new CEO. Dahlen was previously the CEO of SSI Diagnostica.

Innovation Pharmaceuticals

Innovation Pharmaceuticals has welcomed William DeGrado, a professor of pharmaceutical chemistry at the University of California, San Francisco, as the company’s new scientific adviser.

Klick Health

Pharmaceutical and healthcare agency Klick Health has found its new CEO in Lori Grant, who previously served as president of the company.

Kronos Bio

Kronos Bio has named Yasir Al-Wakeel chief financial officer and head of corporate development. Prior to this appointment, Al-Wakeel served as chief financial and strategy officer at Neon Therapeutics.

Kura Oncology

Stephen Dale has been named chief medical officer of Kura Oncology. Previously, Dale was senior vice president and global head of medical science at Kyowa Kirin.

Leap Therapeutics

Leap Therapeutics has appointed Jason Baum to the role of vice president and head of translational medicine and Christine Granfield to vice president and head of regulatory affairs and quality. Baum was most recently executive director and precision medicine leader of general medicine and lung cancer at Novartis Oncology Precision Medicine. Granfield most recently served as an independent regulatory consultant with Granfield Associates.

Merck

Liz Henderson has been named regional vice president of Merck Biopharma Asia Pacific, succeeding Andre Musto who has been promoted to senior vice president and head of the global cardiometabolic and endocrinology franchise. Henderson was recently the general manager of Merck UK.

Omega Therapeutics

Omega Therapeutics has appointed Barbara Chan to vice president of finance and Joe Newman to vice president of biology. Formerly, Chan was vice president of finance and chief accounting officer of Aegerion Pharmaceuticals, and Newman served as vice president of early development at Zikani Therapeutics.

Persomed

Kristof Vercruysse, former chief development officer and chief medical officer of TargED Biopharmaceuticals, is now CEO of Persomed.

POINT Biopharma

POINT Biopharma has appointed new personnel to key roles at the company, including Jessica Jensen to executive vice president of clinical development, Valerie Hergott to senior director of chemistry, manufacturing and controls, and Bill Demers to chief financial officer. Prior to joining POINT, Jensen held the role of senior vice president of clinical development at Progenics Pharmaceuticals, Hergott served as director of radiopharmaceutical development and supply at the Centre for Probe Development and Commercialization, and Demers was the chief financial officer of AgMedica Bioscience.

Rome Therapeutics

Rome Therapeutics has tapped Dennis Zaller to be the company’s new chief scientific officer. Zaller was most recently executive director of integrative sciences at Bristol Myers Squibb.

Sanifit

Adam Levy has been hired by Sanifit to serve as the company’s new chief financial officer. Levy recently served as chief business officer with Brickell Biotech.

Saniona

Clinical stage biopharmaceutical company Saniona has announced the appointment of Jason Amello to the role of chief financial officer. Most recently, Amello was senior vice president and chief financial officer of Akebia Therapeutics. Saniona also appointed Trista Morrison to chief communications officer and Linea Aspesi to chief human resources officer. Morrison previously served as vice president of communications and patient advocacy for rare disease company Sobi, while Aspesi most recently served as vice president and head of human resources and office management for Sobi.

STADAPHARM

Anders Fogstrup, former managing director at Mundipharma, will now serve as the general manager of German pharmaceutical company STADAPHARM.

uniQure

Ricardo Dolmetsch has been named president of research and development at uniQure. Prior to this role, Dolmetsch was global head of neuroscience at Novartis Institutes for Biomedical Research.

Xeris Pharmaceuticals

Xeris Pharmaceuticals has appointed John Shannon to president, which will be an addition to his current role of chief operating officer.

Zai Lab

F. Edmondson has been named chief legal officer of Zai Lab. Most recently, Edmondson was senior vice president and chief corporation counsel and assistant secretary at Biogen.